Genzyme, Procter & Gamble deal

PG licensed exclusive worldwide rights to develop, commercialize and manufacture GENZ's RDP58 to treat gastrointestinal and other disorders. PG initially will focus on trials in ulcerative colitis. GENZ retains rights in pulmonary and other indications, and will have co-promotion rights in oncology-related disorders such as chemotherapy-induced diarrhea. GENZ will receive upfront payments of up to $10 million and is eligible for milestones and royalties. PG is responsible for all future development in licensed indications. ...